Ponatinib Dose-Ranging Study Shows Efficacy in Chronic-Phase CML Patients
A phase 2 trial evaluating ponatinib in chronic-phase chronic myeloid leukemia (CP-CML) patients resistant to prior tyrosine kinase inhibitors (TKIs) demonstrated significant efficacy across three starting doses. The study highlighted a novel, response-based dose-reduction strategy, with the 45 mg starting dose showing optimal benefit/risk outcomes when reduced to 15 mg upon achieving a response.
© Copyright 2025. All Rights Reserved by MedPath